Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine
Authors:
- 28 February 2008
- journal article
- other
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 22 (3) , 323-329
Abstract
The Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS) was developed to provide a comprehensive measure for rating non-neurological adverse drug reactions (ADRs) to antipsychotics. Although there were already available measures that adequately rated specific non-neurological ADRs, such as sexual side effects, a need was identified for a scale that comprehensively rated the full range of non-neurological ADRs commonly seen across the spectrum of first and second generation antipsychotic drugs, including metabolic and autonomic ADRs. This article reports on work to establish the interrater reliability of an early version and a later, more comprehensive version of the ANNSERS (versions 1 and 2, v1 and v2, respectively). The measures were administered in London centres to patients treated with clozapine. Trained clinicians rated the patients simultaneously and independently. Interrater reliability on the scores was calculated using the kappa coefficient method. The results (mean kappa coefficients of 0.77 and 0.72, respectively) indicate that substantial interrater reliability was achieved for both versions. Items for which the main basis for rating was laboratory investigations rather than patient interview were largely excluded from this study, and kappas were also not calculated for items with a low frequency (less than 10%) of endorsement. Samples of patients on other antipsychotics would be required to reliably calculate kappa coefficients for these items. In conclusion, the ANNSERS represents a clinically applicable research innovation, with good interrater reliability on clinician judged items, which is now available for the comprehensive assessment of non-neurological ADRs to antipsychotics, to aid the processes of clinical audit, research and drug discovery.Keywords
This publication has 27 references indexed in Scilit:
- Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemiaJournal of Psychopharmacology, 2007
- Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in SchizophreniaArchives of General Psychiatry, 2006
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- Physical Health Monitoring of Patients With SchizophreniaAmerican Journal of Psychiatry, 2004
- Antipsychotic-Induced HyperprolactinaemiaDrugs, 2004
- A Meta-analysis of the Efficacy of Second-Generation AntipsychoticsArchives of General Psychiatry, 2003
- A Self-Rating Scale for Measuring Neuroleptic Side-EffectsThe British Journal of Psychiatry, 1995
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.Psychological Bulletin, 1968